← All perspectives

Company · Healthcare · Equity · 2025–2026

The Trust Gap: Turning a $50 Generic Into a Branded Franchise the Whole System Wants

Eighteen million prescriptions a year treat opioid addiction with a molecule that costs $50 a month — and roughly three in four patients fall out of treatment within six months. Infer closes that gap with a device that turns daily proof of adherence into something providers, payers, and courts will pay branded-drug prices for.

Every day in America, roughly 190 people die of an opioid overdose. Almost half of those deaths happen in the two weeks after someone leaves treatment.

That single fact defines the opportunity. We know how to treat opioid use disorder: buprenorphine cuts overdose and all-cause mortality by 60–80%. The medicine works. What fails is staying on it. Only 26.6% of patients who start buprenorphine are still adherent at 180 days. The other three-quarters drift out of treatment and back toward the overdose window — and the system has almost no way to see it happening until it's too late.

This is not a drug-discovery problem. The molecule is generic, effective, and cheap — buprenorphine-naloxone films run about $50 a month. It is a proof problem. And proof, in this market, is worth more than the drug.

The Trust Gap

Recovery runs on a relationship that is quietly broken. A prescriber writing buprenorphine has to play two incompatible roles: healer and enforcer. They want to extend trust — more take-home doses, telehealth visits, longer scripts, the autonomy that helps people rebuild a life. But diversion is real, liability is severe (opioids are 5% of prescriptions but 24% of medication-error and overdose claims), and the only tools they have to verify adherence are crude and adversarial: urine cups at office visits, pill counts, and a patient's word.

So the system defaults to suspicion. Patients who could be trusted get treated like they can't. Patients who are struggling hide it, because admitting a missed dose risks getting "fired" from treatment. Providers, in one physician's words, are forced to "operate like probation officers." Everyone loses the thing recovery depends on most.

We call this the Trust Gap: the distance between what a provider could safely allow and what they can prove is safe — a gap filled today with blunt restriction because no better instrument exists.

Close that gap with objective, daily evidence, and the whole relationship inverts. The patient earns autonomy instead of pleading for it. The provider extends trust backed by data instead of withholding it out of fear. And for the first time, the trust itself becomes measurable — which is what turns it into an asset the rest of the system will pay for.

Why This Reprices the Whole Category

Infer's lead product, BunaTrack, is deceptively simple: the same generic buprenorphine-naloxone, packaged in tamper-evident cartridges that dispense one authorized dose at a time through a smart device that timestamps every access, caps the daily dose, and prompts randomized lab confirmation. Miss a dose, divert a dose, and the record shows it in real time. Take it as prescribed, and you accumulate a verifiable history of trust.

The structural insight is what makes this an investment rather than a gadget. BunaTrack is a drug-device combination product going through the FDA's 505(b)(2) pathway — the same route that turned injectable buprenorphine into Indivior's Sublocade. That pathway lets a known molecule, delivered a new way, return to market as an approved new drug: a distinct FDA label, its own billing code, and brand pricing on a molecule that otherwise trades as a commodity. It is the mechanism by which a $50 generic becomes something the system reimburses like a franchise.

The precedent is not hypothetical. Payers already pay a 15–25x premium for adherence-advantaged buprenorphine: Sublocade lists above $2,000 a month against that $50 generic, and grew from 28,900 patients in 2020 to over 170,000 in 2024 — roughly $756 million in 2024 net revenue — while raising price, because it solved a slice of the same adherence problem. The market has already voted that proof of adherence is worth an order of magnitude more than the drug. BunaTrack extends that logic to the 18 million oral prescriptions Sublocade's injection never reached.

A Market Already in the Room

The rarest thing in healthcare is a novel product that doesn't need to create demand. BunaTrack doesn't.

18.3 million buprenorphine prescriptions were dispensed in the US in 2024. This is not a market to be built; it is a market to be converted — patients already diagnosed, already prescribed, already covered, sitting in the practices of a concentrated prescriber base where roughly the top 5,000 high-volume sites write the large majority of scripts. A commercial team doesn't need to find the patients. It needs to reach the prescribers who already have them.

And the economics of conversion favor everyone at the table:

  • Payers carry the cost of failure. An uncontrolled OUD patient can cost a plan $60,000+ a year; keeping that patient in stable treatment roughly halves it. Every additional day of adherence saves a payer money — the literature puts it near $29 per adherent day. A product that manufactures adherence is, to a payer, a cost-reduction instrument that happens to look like a drug.
  • Providers get a liability shield and a new revenue line — remote-monitoring reimbursement codes pay them to review the very data BunaTrack generates — while offloading the policing role they never wanted.
  • Courts and Medicaid get what they've never had: verifiable proof that a mandated patient is actually taking their medication. Drug courts and correctional systems restrict buprenorphine specifically because they can't control diversion; BunaTrack removes the reason for the restriction.

The reimbursement rail already exists. The demand already exists. The molecule already exists. What hasn't existed is the proof layer — and that is the whole company.

What Our Investment Unlocks — and the Operator Bet

1V1sion led Infer's round with a specific conviction: the technology and regulatory work were largely de-risked, but the company needed operators who had sold into this exact market. We pushed hard on that, and the company delivered.

The commercialization team is now built from the people who created the comparable franchise. Infer's Chief Commercial Officer ran the commercialization of Sublocade at Indivior — the very product that proved payers will pay brand prices for buprenorphine adherence, scaled from roughly $12 million to $800 million in annual revenue. The head of sales brings 14 years of Indivior OUD field leadership. The chief medical and regulatory officer is a former FDA medical officer. This is not a team learning the addiction market; it is the team that built the last winner in it, now holding a product that reaches ten times as many patients.

That is the heart of the bet. The science is proven, the pathway is filed, the market is in place. The remaining question in any specialty-pharma launch is execution — and we have specifically underwritten the people who have executed this exact motion before.

The Upside, Priced by Precedent

The value chain is visible. A 505(b)(2) asset with real exclusivity and a differentiated label prices like branded specialty pharma, not like a generic or a device. Recently approved 505(b)(2) assets with durable exclusivity have transacted at roughly 3–6x net revenue, and the natural acquirers are already consolidating this exact space: Indivior, Alkermes, and the injectable-buprenorphine players (Camurus was reported in talks to acquire Braeburn for around $1 billion in 2025) all need to defend and extend their OUD franchises. A product that converts the oral market they can't reach is a strategic asset to every one of them.

Behind the lead product sits a platform. The same locked-cartridge, proof-of-adherence architecture applies to any drug where misuse, diversion, or adherence carries high stakes — post-surgical opioids, stimulants, immunosuppressants, oral oncolytics. Each is a separate 505(b)(2) shot on goal using infrastructure already built and patents already granted. The lead product is the proof; the platform is the option value.

What Protects the Downside

We underwrite Infer as a late-stage regulatory catalyst with venture upside — and we size the risk honestly.

  • A near-term, binary catalyst. The FDA submission is accepted and under review; value inflects on approval, on a defined timeline, not on years of open-ended discovery.
  • Deep IP. Eleven active US patents across three interlocking families — dose-access control, the inference engine, and the secure cartridge — that the company estimates would take a well-funded competitor four-plus years to design around.
  • A molecule that already works. No efficacy risk on the drug itself; buprenorphine's clinical record is decades deep. The innovation is delivery and proof, not pharmacology.
  • Aligned, proven operators. A founder with more than $6 million of his own capital in, and a commercial team that built the category's last success.
  • Platform optionality. Value doesn't rest on a single product; the architecture extends across multiple high-stakes drug categories.

The honest risks are specific and we name them. This is a binary regulatory event — approval timing has already moved, and a delay defers the catalyst. Reimbursement coding for a novel drug-device combination must be established, not assumed. The pivotal clinical evidence, while striking — 97% of days adherent versus 72% in company studies — rests on small samples that a launch will need to scale. And commercial traction today is serious interest, not yet signed contracts. What this investment does not require: inventing a molecule, creating demand, or changing physician behavior against their interest. Every incentive in the room already points toward adoption.

One more force works in the background. Overdose deaths finally fell sharply in 2024 — down roughly 27% — as treatment and naloxone access expanded. That progress is fragile and adherence-dependent, and more than $50 billion in opioid-settlement money is flowing to states with a mandate to fund exactly this kind of treatment. The tailwind is real and paying.

The addiction market has spent two decades trying to close the trust gap with restriction. Infer closes it with proof — and proof, in this system, is what gets paid like a brand.

The full underwriting file — regulatory status, clinical data, and commercial model — is available to qualified investors. If healthcare, specialty pharma, or the economics of the opioid crisis is on your radar, we're glad to walk through the work.